FDA again reviewing MannKind's Afrezza

FDA accepted for review a resubmitted NDA from MannKind Corp. (NASDAQ:MNKD) for Afrezza to improve glycemic control in Type I and II diabetics. The PDUFA date is April 15, 2014. The resubmission inclu...